GCK Antibody (G-6): sc-17819

GCK Antibody (G-6) is a mouse monoclonal IgG1 kappa light chain antibody that detects GCK protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-GCK antibody (G-6) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Glucokinase, also known as hexokinase IV, plays a crucial role in glucose metabolism and is primarily located in pancreatic beta cells and the liver. In pancreatic beta cells, GCK acts as a glucose sensor, regulating insulin secretion in response to blood glucose levels, which is vital for maintaining glucose homeostasis. In the liver, GCK catalyzes the phosphorylation of glucose, marking the first committed step in glucose disposal. This enzymatic activity is essential because it determines the rate at which glucose is metabolized, and any dysfunction in GCK can lead to significant metabolic disorders. For instance, mutations in the GCK gene are associated with maturity onset diabetes of the young (MODY), highlighting the importance of this protein in both insulin regulation and glucose metabolism. GCK monoclonal antibody (G-6) effectively detects and quantifies GCK, making this antibody an invaluable tool for research into diabetes and metabolic diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

GCK Antibody (G-6) References:

1. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia.  |  Osbak, KK., et al. 2009. Hum Mutat. 30: 1512-26. PMID: 19790256
2. Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts.  |  Mirshahi, UL., et al. 2022. Am J Hum Genet. 109: 2018-2028. PMID: 36257325
3. Inhibition of Hmbox1 Promotes Cardiomyocyte Survival and Glucose Metabolism Through Gck Activation in Ischemia/Reperfusion Injury.  |  Bei, Y., et al. 2024. Circulation. 150: 848-866. PMID: 38708602
4. Glucokinase (GCK) in diabetes: from molecular mechanisms to disease pathogenesis.  |  Abu Aqel, Y., et al. 2024. Cell Mol Biol Lett. 29: 120. PMID: 39245718
5. Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis.  |  Grupe, A., et al. 1995. Cell. 83: 69-78. PMID: 7553875
6. Upregulated hexokinase activity in isolated islets from diabetic 90% pancreatectomized rats.  |  Hosokawa, H., et al. 1995. Diabetes. 44: 1328-33. PMID: 7589832
7. Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression.  |  De Vos, A., et al. 1995. J Clin Invest. 96: 2489-95. PMID: 7593639
8. Variable effects of maturity-onset-diabetes-of-youth (MODY)-associated glucokinase mutations on substrate interactions and stability of the enzyme.  |  Liang, Y., et al. 1995. Biochem J. 309 (Pt 1): 167-73. PMID: 7619052
9. Animal model for maturity-onset diabetes of the young generated by disruption of the mouse glucokinase gene.  |  Bali, D., et al. 1995. J Biol Chem. 270: 21464-7. PMID: 7665557
10. Glucose regulates the maximal velocities of glucokinase and glucose utilization in the immature fetal rat pancreatic islet.  |  Tu, J. and Tuch, BE. 1996. Diabetes. 45: 1068-75. PMID: 8690154
11. The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells.  |  Heimberg, H., et al. 1996. Proc Natl Acad Sci U S A. 93: 7036-41. PMID: 8692940
12. Correction of diabetic alterations by glucokinase.  |  Ferre, T., et al. 1996. Proc Natl Acad Sci U S A. 93: 7225-30. PMID: 8692973

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-GCK Antibody (G-6) has 18 citations in a variety of scientific publications.

Primary antibodies like Anti-GCK Antibody (G-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

GCK Antibody (G-6) Specifications

Alternate Product Name: Glucokinase

Product Clone Name: G-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 318-405

Epitope Target: GCK

Epitope Species: human

Product Reactivity/Detection: GCK

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 18 citations in various scientific publications

Available Conjugates/Forms for GCK Antibody (G-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin